Core Insights - Aimeike (300896) is a leading domestic enterprise focused on the research and development of biological medical soft tissue repair materials, being the first in China to obtain a Class III medical device registration for injectable sodium hyaluronate [1][2] - The company aims to enhance the quality and dignity of life through technological innovation, establishing a comprehensive product matrix in medical aesthetics, dermatology, major surgery, and metabolic disease treatment [1][2] R&D and Innovation - Aimeike maintains a high level of investment in core technology research, with a projected R&D expenditure of 304 million yuan in 2024, accounting for 10.04% of revenue [2] - The company has established key technology platforms and holds 163 effective authorized patents, including 49 invention patents, as of the end of 2024 [2] - A significant investment of 810 million yuan in the "Beautiful Health Industrialization Innovation Construction Project" is expected to support the launch of over 20 new Class III medical devices in the next seven years [2] Industry Collaboration - The company has initiated a collaborative model with top universities and research institutions, funding 38 projects with a total of 20.4 million yuan through the "Beijing Natural Science Foundation - Changping Innovation Joint Fund" [2] - Aimeike collaborates with nearly 50 domestic and international hospitals and research units on evidence-based medical research, resulting in over 80 global collaborative projects and nearly 80 high-level publications [2] Market Position and Social Responsibility - Aimeike's core products maintain a leading market share, with the "Ru White Angel" product generating over 3 billion yuan in cumulative output value [3] - The company has been recognized as a leader in the medical aesthetics industry, receiving the "2025 China Medical Aesthetics Industry Leader Enterprise Award" from the China Association of Plastic Surgery and Aesthetic Medicine [3] - Aimeike actively engages in social responsibility initiatives, donating 5 million yuan to launch the "Happy Tomorrow: New Beauty Mom" charity project and 1 million yuan to support victims of the Hong Kong Tai Po fire [3] Future Outlook - As a leader in the medical aesthetics industry, Aimeike is set to continue driving high-quality development and industry transformation through ongoing international expansion and the introduction of new technologies and products [3]

Core Insights - AbbVie’s global aesthetics leader, Allergan Aesthetics, is driving unprecedented innovation in China's aesthetic industry, aiming to collaborate with local biotech firms and industry platforms to foster high-quality technologies and solutions from China [1][2] Group 1: Event Overview - The "China Innovation Collaboration Day" hosted by Allergan Aesthetics in Shanghai gathered leaders from the medical aesthetics industry, investment sector, and upstream innovation fields to discuss trends, R&D progress, commercialization, and industry investment [1] - The event featured the launch of the "AbbVie China Innovation Award (Aesthetics Award)," which aims to identify and empower early-stage technologies and projects in the medical aesthetics sector [1][2] Group 2: Innovation Award Details - The innovation award will select promising early-stage biotech companies and provide a support package valued at 500,000 yuan, including access to high-standard laboratories, office space, R&D team support, and professional advice on R&D, production, quality, and compliance [2] - Allergan Aesthetics emphasizes the importance of aligning technological breakthroughs with localized service systems, aiming to create a sustainable and replicable innovation model in China [2] Group 3: Future Development Plans - Allergan Aesthetics plans to maintain an open collaboration approach, adhering to global quality and scientific standards while supporting the cultivation and development of high-quality local innovation projects [2]